



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: <b>G01N 33/543, G01N 21/47</b>	<b>A1</b>	(11) International Publication Number: <b>WO 00/36416</b>
		(43) International Publication Date: 22 June 2000 (22.06.2000)

(21) International Application Number: PCT/US99/27727

(22) International Filing Date: 22 November 1999 (22.11.1999)

(30) Priority Data:  
09/213,713 17 December 1998 (17.12.1998) US(60) Parent Application or Grant  
KIMBERLY-CLARK WORLDWIDE, INC. [/];  
(). MCGRATH, Kevin [/]; (). KAYLOR, Rosann, M. [/];  
(). EVERHART, Dennis, S. [/]; (). GREEN, Theodore, M. ; ().

Published

(54) Title: PATTERNED DEPOSITION OF ANTIBODY BINDING PROTEINS FOR OPTICAL DIFFRACTION-BASED BIOSENSORS

(54) Titre: DEPOT EN MOTIF DE PROTEINES FIXANT LES ANTICORPS, POUR BIOCAPTEURS A BASE DE DIFFRACTION OPTIQUE

## (57) Abstract

The present invention provides an inexpensive and sensitive device and method for detecting and quantifying analytes present in a medium. The device comprises a metalized film upon which is printed a specific, predetermined pattern of an antibody-binding protein. Upon attachment of a target analyte to select areas of the plastic film upon which the protein is printed, diffraction of transmitted and/or reflected light occurs via the physical dimensions and defined, precise placement of the analyte. A diffraction image is produced which can be easily seen with the eye or, optionally, with a sensing device.

## (57) Abrégé

L'invention concerne un dispositif bon marché et sensible et un procédé de détection et de quantification d'analytes présents dans un milieu. Ledit dispositif comprend un film métallisé sur lequel est imprimé un motif prédéterminé spécifique de protéines fixant les anticorps. Lors de la fixation d'un analyte cible sur les zones sélectionnées du film plastique sur lequel la protéine est imprimée, on constate une diffraction de la lumière émise et/ou réfléchiée en fonction des dimensions physiques et du placement précis et défini de l'analyte. Une image de diffraction facilement visible à l'oeil nu ou éventuellement au moyen d'un dispositif de détection, est produite.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : <b>G01N 33/543, 21/47</b>		A1	(11) International Publication Number: <b>WO 00/36416</b>
			(43) International Publication Date: 22 June 2000 (22.06.00)
(21) International Application Number: PCT/US99/27727		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 22 November 1999 (22.11.99)		<p>Published With international search report.</p>	
(30) Priority Data: 09/213,713 17 December 1998 (17.12.98) US			
(71) Applicant: KIMBERLY-CLARK WORLDWIDE, INC. [US/US]; 401 North Lake Street, Neenah, WI 54956 (US).			
(72) Inventors: MCGRATH, Kevin; 335 Hermitage Trail, Alpharetta, GA 30004 (US). KAYLOR, Rosann, M.; 7480 Williamsburg Drive, Cumming, GA 30041 (US). EVERHART, Dennis, S.; 230 Hereford Road, Alpharetta, GA 30004 (US).			
(74) Agents: GREEN, Theodore, M.; Jones & Askew, LLP, 2400 Monarch Tower, 3424 Peachtree Road, N.E., Atlanta, GA 30326 (US) et al.			

(54) Title: PATTERNED DEPOSITION OF ANTIBODY BINDING PROTEINS FOR OPTICAL DIFFRACTION-BASED BIOSENSORS

(57) Abstract

The present invention provides an inexpensive and sensitive device and method for detecting and quantifying analytes present in a medium. The device comprises a metalized film upon which is printed a specific, predetermined pattern of an antibody-binding protein. Upon attachment of a target analyte to select areas of the plastic film upon which the protein is printed, diffraction of transmitted and/or reflected light occurs via the physical dimensions and defined, precise placement of the analyte. A diffraction image is produced which can be easily seen with the eye or, optionally, with a sensing device.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	VU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LJ	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**Description**

5

10

15

20

25

30

35

40

45

50

55

5

10

5

15

10

## **PATTERNED DEPOSITION OF ANTIBODY BINDING PROTEINS FOR OPTICAL DIFFRACTION-BASED BIOSENSORS**

20

### **TECHNICAL FIELD**

15

25

The present invention is generally in the field of detecting analytes in a medium and, more particularly, the present invention relates to micro-contact printing of antibody-binding proteins onto a substrate for the development of single use, disposable sensors to indicate the presence of the analyte in a medium.

30

20

### **BACKGROUND OF THE INVENTION**

35

25

40

30

There are many systems and devices available for detecting a wide variety of analytes in various media. Most of these systems and devices are relatively expensive and require a trained technician to perform the test. There are many cases where it would be advantageous to be able to rapidly and inexpensively determine if an analyte were present. What is needed is a biosensor system that is easy and inexpensive to manufacture and is capable of reliable and sensitive detection of analytes, including smaller analytes. Additionally, what is needed is an easy flexible method of preparation of the biosensors which would permit optimum scale-up processing.

45

35

50

Sandstrom et al., 24 *Applied Optics* 472, 1985, describe use of an optical substrate of silicon with a layer of silicon monoxide and a layer of silicon formed as dielectric films. They indicate that a change in film thickness changes the properties of the optical substrate to produce different colors related to the thickness of the film. The thickness of the film is related to the color observed and a film provided on top of an optical substrate may produce a visible color change. The authors indicate that a mathematical model can be used to quantitate the color change, and that "[c]alculations

55

5 performed using the computer model show that very little can be gained in  
optical performance from using a multilayer structure... but a biolayer on the  
10 surface changes the reflection of such structures very little since the optical  
properties are determined mainly by the interfaces inside the multilayer  
5 structure. The most sensitive system for detection of biolayers is a single  
layer coating, while in most other applications performance can be by  
additional dielectric layers."

15 Sandstrom et al., go on to indicate that slides formed from metal  
oxides on metal have certain drawbacks, and that the presence of metal  
10 ions can also be harmful in many biochemical applications. They indicate  
that the ideal top dielectric film is a 2-3 nm thickness of silicon dioxide which  
is formed spontaneously when silicon monoxide layer is deposited in ambient  
20 atmosphere, and that a 70-95 nm layer silicon dioxide on a 40-60 nm layer of  
silicon monoxide can be used on a glass or plastic substrate. They also  
15 describe formation of a wedge of silicon monoxide by selective etching of  
the silicon monoxide, treatment of the silicon dioxide surface with  
dichlorodimethylsilane, and application of a biolayer of antigen and  
25 antibody. From this wedge construction they were able to determine film  
thickness with an ellipsometer, and note that the "maximum contrast was  
found in the region about 65 nm where the interference color changed from  
30 purple to blue." They indicate that the sensitivity of such a system is high  
enough for the detection of protein antigen by immobilized antibodies. They  
conclude "the designs given are sensitive enough for a wide range of  
35 applications. The materials, i.e., glass, silicon, and silicon oxides, are  
chemically inert and do not affect the biochemical reaction studied. Using  
the computations above it is possible to design slides that are optimized for  
different applications. The slides can be manufactured and their quality  
40 ensured by industrial methods, and two designs are now commercially  
available.

30 U.S. Patent 5,512,131 issued to Kumar et al. describes a device that  
includes a polymer substrate having a metal coating. An antibody-binding  
protein layer is stamped on the coated substrate. The device is used in a  
45 process for stamping or as a switch. A diffraction pattern is generated when  
an analyte binds to the device. A visualization device, such as a spectrometer,  
35 is then used to determine the presence of the diffraction pattern.

50 However, the device described by Kumar et al. has several  
disadvantages. One disadvantage is that an extra visualization device is

5 needed to view any diffraction pattern. By requiring a visualization device,  
the Kumar et al. device does not allow a large number of samples to be tested  
since it is not possible to determine the presence of an analyte by using the  
10 unaided eye.

5 U.S. Patent No. 5,482,830 to Bogart, et al., describes a device that  
includes a substrate which has an optically active surface exhibiting a first  
color in response to light impinging thereon. This first color is defined as a  
15 spectral distribution of the emanating light. The substrate also exhibits a  
second color which is different from the first color (by having a combination  
10 of wavelengths of light which differ from that combination present in the first  
color, or having a different spectral distribution, or by having an intensity of  
one or more of those wavelengths different from those present in the first  
20 color). The second color is exhibited in response to the same light when the  
analyte is present on the surface. The change from one color to another can  
be measured either by use of an instrument, or by eye. Such sensitive  
15 detection is an advance over the devices described by Sandstrom and  
Nygren, supra, and allow use of the devices in commercially viable and  
25 competitive manner.

However, the method and device described in the Bogart, et al. patent  
20 has several disadvantages. One disadvantage is the high cost of the device.  
Another problem with the device is the difficulty in controlling the various  
layers that are placed on the wafer so that one obtains a reliable reading.  
What is needed is a biosensor device that is easy and inexpensive to  
30 manufacture and is capable of reliable and sensitive detection of the analyte to  
be detected.  
35 25

#### SUMMARY OF THE INVENTION

40 The present invention provides an inexpensive and sensitive device and  
method for detecting analytes present in a medium. The device comprises a  
30 biosensing device having a substrate, preferably a metalized polymer film,  
upon which is printed a specific predetermined pattern of antibody-binding  
proteins such as Protein A or Protein G. Subsequent exposure to the  
45 antibody specific for the desired analyte results in patterned deposition of this  
antibody. Overall, this allows a modular production format such that large  
35 rolls of patterned protein may be made for use with different analytes. Then  
as needed, the final product may be made by exposure to the necessary  
50 antibody.

5

10

5

Upon attachment of a target analyte, which is capable of scattering light, to select areas of the polymer film upon which the protein and antibody are patterned, diffraction of transmitted and/or reflected light occurs via the physical dimensions and defined, precise placement of the analyte. A diffraction image is produced which can be easily seen with the eye or, optionally, with a sensing device.

15

10

20

15

25

The present invention utilizes methods of contact printing of patterned, antibody-binding proteins. These proteins bind to antibodies to pattern them on the surface as well as maintain the optimum orientation for the receptor antibodies. The receptor antibodies are specific for a particular analyte or class of analyte, depending upon the protein used. Methods of contact printing which would be useful in generating the sensing devices used in the present system are disclosed fully in U.S. Patent Application Nos. 08/707,456 and 08/769,594, both of which are incorporated herein by reference in their entirety. However, since these methods relate to self-assembling monolayers, the methods need to be altered slightly, as discussed below, to print the antibody-binding protein material as this material is not self-assembling.

30

20

35

25

40

30

45

35

50

Patterned antibody-binding protein layers with bound antibodies cause patterned placement or binding of analytes thereon. The biosensing devices of the present invention produced thereby may be used in one of two ways, depending on the size of the analyte. For analytes which are capable of causing diffraction by themselves, such as microorganisms, the system is used by first exposing the biosensing device to a medium that contains the analyte of choice and then, after an appropriate incubation period, transmitting a light, such as a laser, through the film or reflecting it off of the film. If the analyte is present in the medium and is bound to the antibodies on the patterned antibody-binding protein layer, the light is diffracted in such a way as to produce a visible image.

Optionally, for very small analytes such as proteins, the system may utilize "diffraction enhancing elements" which are capable of binding to the target analyte and to the biosensor and are capable of producing a substantial change in the height and/or refractive index, thereby increasing the diffraction efficiency of the biosensor and permitting the detection of smaller analytes. In use, a target analyte attaches either to the diffraction enhancing element, which then attaches to the biosensor, or directly to select areas of the polymer film upon which the protein and antibody are printed. Then

55



5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

diffraction of transmitted and/or reflected light occurs via the physical dimensions and defined, precise placement of the analyte. A diffraction image is produced which can be easily seen with the eye or, optionally, with a sensing device.

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

Another option for use of this sensor involves the detection of analytes which are antibodies. The sensing device could comprise only the patterned antibody-binding proteins, and then would be exposed to the medium plus diffraction enhancing particles which have an antibody specific to the antibody to be detected. The selection of the antibody on the particle is preferably made so that it does not bind non-specifically to the patterned antibody-binding protein, but instead binds only when the analyte antibody is also bound. In this way, the diffraction enhancing elements would cause a substantial change in the height and/or refractive index if the analyte antibody is present, thereby causing a diffraction image to form. It is envisioned that the same format could be used with other immunoassay formats, such as lateral flow assays or microwell plates."

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

In other words, the antibody-binding protein and antibody layers with the analyte bound thereto can produce optical diffraction patterns to indicate the presence of the analyte. The light can be in the visible spectrum, and be either reflected from the film, or transmitted through it, and the analyte can be any compound or particle reacting with the antibody-binding protein layer. The light can be a white light or monochromatic electromagnetic radiation in the visible region. The present invention also provides a flexible support for an antibody-binding protein layer on gold or other suitable metal or metal alloy.

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

The present invention provides a low-cost, disposable biosensor which can be mass produced. It includes the use of surfaces patterned with an antibody-binding protein. Typically, these proteins bind an antibody by its constant region ( $F_c$ ) so that the antibody's antigen-binding regions ( $F_{ab}$ ) are free for optimum binding activity. The preparation of the patterned protein surfaces also allows maximum flexibility in the sensor production. The final step in production, capturing the desired antibody in the patterned areas, may be done as needed for the desired analyte (i.e. at the time of manufacture).

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

The biosensors of the present invention can be produced as a single test for detecting an analyte or it can be formatted as a multiple test device. The biosensors of the present invention can be used to detect contamination in garments, such as diapers, and to detect contamination by microorganisms.

5 The present invention can also be used on contact lenses, eyeglasses, window panes, pharmaceutical vials, solvent containers, water bottles, adhesive bandages, and the like to detect contamination.

10 These and other features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiments.

#### 15 BRIEF DESCRIPTION OF THE FIGURES

10 Figure 1 shows a biosensor capable of simultaneously measuring several different analytes in a medium.

20 Figure 2 is a schematic of contact printing of antibody-binding protein layers, followed by patterned deposition of an antibody.

#### 25 DETAILED DESCRIPTION

15 The present invention features improved biosensing devices, and methods for using such biosensing devices, for detecting and quantifying the presence or amount of an analyte of interest within a medium. The analytes that can be detected by the present invention include, but are not limited to, microorganisms such as bacteria, yeasts, fungi and viruses. In contrast to prior devices, those of the present invention allow detection of extremely small quantities of analyte in a medium in a rapid assay lasting only a few minutes. In addition, no signaling or associated electronic components are required in the biosensing devices of the present invention.

30 20 The present invention comprises micro-contact printing of antibody-binding proteins onto a polymer film, which may also have a metal coating. This allows an easy, modular method of production in that subsequent exposure to an antibody causes its patterned binding. In addition, these proteins may enhance the activity of the immobilized antibody. The present invention allows for the development of single use, disposable biosensors based on light diffraction to indicate the presence of the analyte. Upon attachment of a target analyte to select areas of the plastic film which contain the protein, diffraction of transmitted and/or reflected light occurs via the physical dimensions and defined, precise placement of the analyte. For example, yeast, fungi or bacterium are large enough to act as diffraction elements for visible light when placed in organized patterns on a surface. Additionally, the present invention may include diffraction enhancing elements which increase the diffraction efficiency of the biosensor, thereby

5 making it possible to detect any number of different analytes. In addition to  
producing a simple diffraction image, patterns of analytes can be such as to  
allow for the development of a holographic sensing image and/or a change in  
10 visible color. Thus, the appearance of a hologram or a change in an existing  
5 hologram will indicate a positive response. The pattern made by the  
diffraction of the transmitted light can be any shape including, but not limited to,  
the transformation of a pattern from one pattern to another upon binding  
15 of the analyte to the receptive material. In particularly preferred  
embodiments, the diffraction pattern is discernible in less than one hour  
10 after contact of the analyte with the biosensing device of the present  
invention.

20 The diffraction grating which produces the diffraction of light upon  
interaction with the analyte preferably has a minimum periodicity of the  
wavelength and a refractive index different from that of the surrounding  
15 medium. Very small analytes, such as viruses or molecules, can be detected  
indirectly by using a larger particle that is specific for the small analyte. In  
one embodiment in which the small analyte can be detected comprises  
coating the particle, such as a latex bead, with a protein material that  
specifically binds to the analyte of interest. Particles that can be used in the  
20 present invention include, but are not limited to, glass, cellulose, synthetic  
polymers or plastics, latex, polystyrene, polycarbonate, proteins, bacterial or  
fungal cells and the like. The particles are preferably spherical in shape, but  
the structural and spatial configuration of the particles is not critical to the  
30 present invention. For instance, the particles could be slivers, ellipsoids,  
cubes, and the like. A desirable particle size ranges from a diameter of  
approximately 0.2  $\mu\text{m}$  to 50.0  $\mu\text{m}$ , desirably between approximately 0.4  $\mu\text{m}$   
25 to 1  $\mu\text{m}$ . The composition of the particle is not critical to the present  
invention.

40 The antibody which is immobilized/patterned on the surface will  
specifically bind to an epitope on the analyte that is different from the epitope  
used in the binding to the diffraction enhancing element. Thus, for detecting  
30 a medium with a small analyte, such as viral particles, the medium is first  
exposed to the diffraction enhancing element particles, such as latex particles,  
to which the viral particles bind. Then, the diffraction enhancing element  
45 particles are optionally washed and exposed to the polymer film with the  
antibody-binding protein layers containing the virus specific antibodies. The  
35 antibodies then bind to the viral particles on the element particle thereby

5 immobilizing the element particles in the same pattern as the antibodies on  
the film. Because the bound element particles will cause diffraction of the  
visible light, a diffraction pattern is formed, indicating the presence of the viral  
10 particle in the liquid. Additionally, the polymer film may include a metal  
5 coating thereon. The antibody-binding protein layer would then be located  
on the metalized surface of the film.

15 Alternatively, the analyte may be detected by first exposing the  
substrate to the medium containing the analyte and causing the analyte to  
bind to the antibody-binding protein layer material containing the analyte-  
10 specific antibody. Next, a solution containing the diffraction enhancing  
element particles is contacted with the substrate having the analyte bound  
20 thereto. The particles then bind to the analyte. Because the bound element  
particles will cause diffraction of the visible light, a diffraction pattern is  
formed, indicating the presence of the analyte in the liquid.

15 Finally, in a preferred embodiment, the biosensor, the diffraction  
enhancing element particles and the medium containing the analyte may be  
25 admixed simultaneously. This will result in a combination of the binding  
procedures discussed above. Some of the analytes will first bond with a  
diffraction enhancing element particle prior to binding to the substrate. Other  
30 analytes will first bind with the substrate and then bind with an element  
particle. When a point-light source is shown through the sensor, a diffraction  
pattern is formed, indicating the presence of the analyte in the liquid.

35 The analytes that are contemplated as being detected using the present  
invention include, but are not limited to, bacteria; yeasts; fungi; viruses;  
25 rheumatoid factor; antibodies, including, but not limited to IgG, IgM, IgA and  
IgE antibodies; carcinoembryonic antigen; streptococcus Group A antigen;  
viral antigens; antigens associated with autoimmune disease; allergens; tumor  
antigens; streptococcus Group B antigen; HIV I or HIV II antigen; or host  
40 response (antibodies) to these and other viruses; antigens specific to RSV or  
host response (antibodies) to the virus; an antigen; enzyme; hormone;  
30 polysaccharide; protein; lipid; carbohydrate; drug or nucleic acid; *Salmonella*  
*species*; *Candida species*, including, but not limited to *Candida albicans* and  
45 *Candida tropicalis*; *Salmonella species*; *Neisseria meningitides* groups A, B,  
C, Y and W sub 135, *Streptococcus pneumoniae*, *E. coli K1*, *Haemophilus*  
35 *influenza* type B; an antigen derived from microorganisms; a hapten, a drug  
of abuse; a therapeutic drug; an environmental agent; and antigens specific to  
50 hepatitis.

5

10

15

10

20

15

25

30

35

40

30

45

35

50

55

In another embodiment of the present invention, nutrients for a specific class of microorganisms can be incorporated into the antibody-binding protein layer. In this way, very low concentrations of microorganisms can be detected by first contacting the biosensor of the present invention with the nutrients incorporated therein and then incubating the biosensor under conditions appropriate for the growth of the bound microorganism. The microorganism is allowed to grow until there are enough organisms to form a diffraction pattern. Of course, in some cases, the microorganism can multiply enough to form a diffraction pattern without the presence of a nutrient on the patterned monolayer.

A part of the present invention is the method used to pattern receptors such as antibodies onto a polymer film or a metalized polymer film. The method entails microcontact printing proteins that bind to antibodies. These proteins can include, but are not limited to, Protein A, Protein G, Protein L, as well as their recombinant forms. Commercial versions, such as Zymed's (San Francisco, CA) KAPPALOCK™, are also suitable. Thus, the protein material is defined as the base material to create a specific binding pair, with the other part comprising an antibody specific to the analyte of interest.

The receptor material that is bound to the patterned protein is characterized by an ability to specifically bind the analyte or analytes of interest. Whatever the selected analyte of interest is, the protein material is designed to bind specifically with the analyte of interest. In the preferred embodiments, the biosensing device is configured and arranged to provide a pattern detectable by eye in response to transmission of polychromatic light when the analyte of interest is sandwiched between the antibody and a diffraction enhancing element. In another embodiment, where the analyte is large enough to diffract light, no diffraction enhancing element may be needed.

In many instances, a "blocker" may be necessary to prevent non-specific binding. The term "blocker" as used herein means a reagent that adheres to the sensor surface so that it "blocks" or prevents non-analyte materials from non-specifically binding to the surface (either in the patterned or un-patterned areas). The blocking step may be done as a post-treatment to a surface which has already been contact printed ("post-block"), and is the standard technique for filling in non-contact printed regions with another thiol. However, the inventors have discovered that a "pre-block" technique is preferred over the post-block technique. In the pre-block technique, the

5 surface of the substrate is pre-treated with a non-thiol containing blocker and then contact printed. Not wishing to be bound to any theory, it is theorized that the contact printed material (usually sulfur containing) displaces the  
10 physisorbed blocker, thereby permitting the antibody-binding protein material to be bound directly to the surface of the substrate. A subsequent post-block may also be performed, if desired. Blockers can include, but are not limited to,  $\beta$ -casein, albumins such as bovine serum albumin, pluronic or other  
15 surfactants, polyethylene glycol, polyvinyl alcohol, or sulfur derivatives of the above compounds, and any other blocking material known to those of ordinary skill in the art.

10 The matrix containing the analyte of interest may be a solid, a gas, or a bodily fluid such as an interstitial fluid, mucous, saliva, urine, fecal material, tissue, marrow, cerebral spinal fluid, serum, plasma, whole blood, synovial sputum, buffered solutions, extracted solutions, semen, vaginal secretions,  
15 pericardial, gastric, peritoneal, pleural, a throat swab or other washes and the like. The analyte of interest may be an antigen, an antibody, an enzyme, a toxin, an environmental agent, a cytoplasm component, pili or flagella component, protein, polysaccharide, drug, or any other material that is capable of being recognized by an antibody. For example, receptor material  
20 for bacteria may specifically bind a surface membrane component, protein or lipid, a polysaccharide, a nucleic acid, or an enzyme. The analyte which is indicative of the bacteria may be a saccharide or polysaccharide, an enzyme, a nucleic acid, a membrane component, a ganglioside or an antibody produced by the host in response to the bacteria. The presence of the analyte  
25 may indicate an infectious disease (bacterial or viral), cancer, an allergy, or other medical disorder or condition. The presence of the analyte may be an indication of water or food contamination or other harmful materials. The analyte may indicate drug abuse or may monitor levels of therapeutic agents.

30 In some cases, the analyte may not simply bind the receptor material, but may cause a detectable modification of the receptor material to occur. This interaction could cause an increase in mass at the test surface or a decrease in the amount of receptor material on the test surface. An example  
45 of the latter is the interaction of a degradative enzyme or material with a specific, immobilized substrate. In this case, one would see a diffraction pattern before interaction with the analyte of interest, but the diffraction pattern would disappear if the analyte were present. The specific mechanism  
35 through which binding, hybridization, or interaction of the analyte with the

5  
receptor material occurs is not important to this invention, but may impact the reaction conditions used in the final assay protocol.

10  
5 In general, the antibody-binding protein may be passively adhered to the substrate layer. If required, functional groups may be conjugated onto the antibody-binding protein to allow its covalent attachment onto the test surface.

15  
10 A wide range of techniques can be used to apply the protein material to the substrate. Test surfaces may be coated with antibody-binding protein by application of solution in discrete arrays or patterns; spraying, ink jet, or other imprinting methods; or by contact printing. The technique selected should minimize the amount of protein material required for coating a large number of test surfaces and maintain the stability/functionality of protein material during application. The technique must also apply or adhere the protein material to the substrate in a very uniform and reproducible fashion.

15  
25 The next step would comprise exposing the patterned surface to the antibody specific for the desired analyte. This could be done by total immersion in a solution for a predetermined period of time, spraying, or spin coating. In addition, controlled placement of various antibodies could lead to a multi-analyte system. Another advantage to this process is the modular format for production. In other words, one system with patterned antibody-binding protein can be optimized and then provide detection of a wide variety of analytes, depending on the antibody bound.

30  
20 The medium in which the analyte may reside can be solid, gel-like, liquid or gas. For purposes of detecting an analyte in a body fluid, the fluid is selected from, but not limited to, urine, serum, plasma, spinal fluid, sputum, whole blood, saliva, uro-genital secretions, fecal extracts, pericardial, gastric, peritoneal, pleural washes, vaginal secretions, or a throat swab; and the method optionally includes using a spectrophotometer to measure the appearance of the refractive pattern. The most common gas that is contemplated as being used with the biosensing device of the present invention is air.

35  
25  
40  
30 The biosensing device of the present invention utilizes methods of contact printing of patterned, antibody-binding proteins on substrates, desirably metalized polymer films, the subsequent exposure to antibody to achieve patterned antibody, the compositions produced thereby, and the use of these compositions. Patterned antibody-binding protein layers allow for the controlled placement of antibodies thereon which can bind an analyte.

5 The term "patterned antibody-binding protein layers" as used herein means the antibody-binding protein plus the desired antibody layers in any pattern on the substrates including a solid pattern.

10 5 When the film with the patterned antibody-binding protein layers is exposed to an analyte that is capable of reacting with the antibody, the film will produce optical diffraction patterns which differ depending on the reaction of the antibody with the analyte of interest. The liquid may be a high surface tension fluid such as water. The light can be in the visible spectrum, and be either reflected from the film, or transmitted through it, and the analyte can be any compound reacting with the patterned antibody-binding protein layer.

15 10 In preferred embodiments, the method involves contacting the substrate with a test sample potentially containing the analyte under conditions in which the substrate causes a change in the refractive index. When light is transmitted through the film with the patterned antibody-binding protein layer, a visible diffraction pattern is formed and can be visualized by directing the light to a surface or by looking directly through the substrate.

20 20 In one embodiment, the present invention is contemplated in a dipstick form in which the micro-contact printed film is mounted at the end of the dipstick. In use the dipstick is dipped into the liquid in which the suspected analyte may be present and allowed to remain for several minutes. The dipstick is then removed and then, either a light is projected through the film or the film is observed with a light behind the film. If a pattern is observed, then the analyte is present in the liquid.

25 25 In another embodiment of the present invention, a multiple analyte test is constructed on the same support. As shown in Figure 1, a strip 10 is provided with several micro-contact printed films 20, 25, 30 and 35, each film having a pattern 40 printed thereon. Each of the micro-contact printed metalized films 15, 20, 25, and 30 have a different antibody that is specific for different analytes. It can be seen that the present invention can be formatted in any array with a variety of micro-contact printed metalized films thereby allowing the user of the biosensor device of the present invention to detect the presence of multiple analytes in a medium using a single test.

30 30 In yet another embodiment of the present invention, the biosensor can be attached to an adhesively backed sticker or decal which can then be placed on a hard surface or container wall. The biosensor can be placed on the



5 inside surface of a container such as a food package or a glass vial. The biosensor can then be visualized to determine the presence of analyte.

10 Typically, a gold film, 5 to 2000 nm thick, is supported on a titanium-primed polyethylene-terephthalate film, Si/SiO<sub>2</sub> wafer or glass sheet. The titanium serves as an adhesion promoter between gold and the support. The antibody-binding protein attaches to the gold surface during contact printing.

15 Figure 2 outlines the procedure used for microcontact printing. An elastomeric stamp is used to transfer antibody-binding protein "ink" to a surface by contact; if the stamp is patterned, a patterned antibody-binding protein layer forms. The stamp is fabricated by casting polydimethylsiloxane (PDMS) on a master having the desired pattern. Masters are prepared using standard photolithographic techniques, or constructed from existing materials having microscale surface features.

20 In a preferred embodiment of a typical experimental procedure, a photolithographically produced master is placed in a glass or plastic Petri dish, and a 10:1 ratio (w:w) mixture of SYLGARD® silicone elastomer 184 and SYLGARD® silicone elastomer 184 curing agent (Dow Corning Corporation) is poured over it. The elastomer is allowed to sit for approximately 30 minutes at room temperature and reduced pressure to degas, then cured for at least 4 hours at 60°C, and gently peeled from the master. "Inking" of the elastomeric stamp is accomplished by exposing the stamp to a 0.1 to 10 µM aqueous solution of disulfide-derivatized antibody-binding protein typically by placing the stamp face down in the solution for 10 seconds to 10 minutes. The stamp is allowed to dry, either under ambient conditions, or typically by exposure to a stream of air or nitrogen gas. Following inking, the stamp is applied to a gold surface. Light pressure is used to ensure complete contact between the stamp and the surface. After 1 second to 5 minutes, the stamp is then gently peeled from the surface. Following removal of the stamp, the surface is rinsed and dried. Alternatively, further derivatization of unstamped areas can be accomplished, either by using a second stamp or by exposing the entire surface with a different reagent. Subsequently, exposure to a protein-blocking agent, such as BSA or β-casein, or any other agent well known in the art, can also be done. After the pattern is positioned, the patterned surface would be exposed to an antibody specific for the desired analyte either by immersion in a

5 solution or by spraying or spin coating the solution onto the patterned surface.

10 The elastomeric character of the stamp is important to the success of the process. Polydimethylsiloxane (PDMS), when cured, is sufficiently elastomeric to allow good conformal contact of the stamp and the surface, even for surfaces with significant relief; this contact is essential for efficient contact transfer of the protein to the gold film. The elastomeric properties of PDMS are also important when the stamp is removed from the master: if the stamp were rigid (as is the master) it would be difficult to separate the stamp and master after curing without damaging one of the two substrates. PDMS is also sufficiently rigid to retain its shape, even for features with sub-micron dimensions. The surface of PDMS has a low interfacial free energy ( $\gamma = 22.1$  dynes/cm), and the stamp does not adhere to the gold film. The stamp is durable in that the same stamp can be used up to 100 times over a period of several months without significant degradation in performance. The polymeric nature of PDMS also plays a critical role in the inking procedure, by enabling the stamp to absorb the protein ink by swelling.

15 A more detailed description of the methods and compositions of the present invention follows. All publications cited herein are incorporated by reference in their entirety.

20 Any plastic film is suitable for the present invention. Preferably, the plastic film is also capable of having a metal coating deposited thereon. These include, but are not limited to polymers such as: polyethylene-terephthalate (MYLAR®), acrylonitrile-butadiene-styrene, acrylonitrile-methyl acrylate copolymer, cellophane, cellulosic polymers such as ethyl cellulose, cellulose acetate, cellulose acetate butyrate, cellulose propionate, cellulose triacetate, cellulose triacetate, polyethylene, polyethylene - vinyl acetate copolymers, ionomers (ethylene polymers) polyethylene-nylon copolymers, polypropylene, methyl pentene polymers, polyvinyl fluoride, and aromatic polysulfones. Preferably, the plastic film has an optical transparency of greater than 80%. Other suitable thermoplastics and suppliers may be found, for example, in reference works such as the *Modern Plastics Encyclopedia* (McGraw-Hill Publishing Co., New York 1923-1996).

25 In one embodiment of the invention, the polymer film has a metal coating thereon and has an optical transparency of between approximately 5% and 95%. A more desired optical transparency for the thermoplastic film used in the present invention is between approximately 20% and 80%. In a

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

desired embodiment of the present invention, the polymer film has at least an approximately 80% optical transparency, and the thickness of the metal coating is such as to maintain an optical transparency greater than about 20%, so that diffraction patterns can be produced by either reflected or transmitted light. This corresponds to a metal coating thickness of about 10 nm. However, in other embodiments of the invention, the gold thickness may be between approximately 1 nm and 1000 nm.

The preferred metal for deposition on the film is gold. However, silver, aluminum, chromium, copper, iron, zirconium, platinum and nickel, as well as oxides of these metals, may be used.

In principle, any surface with corrugations of appropriate size could be used as masters. The process of microcontact printing starts with an appropriate relief structure, from which an elastomeric stamp is cast. This 'master' template may be generated photolithographically, or by other procedures, such as commercially available diffraction gratings. In one embodiment, the stamp may be made from polydimethylsiloxane.

In another embodiment, the invention features an optical assay device, having an optically active receptive surface configured and arranged to allow simultaneous assay of a plurality of samples on the surface for one analyte of interest, and an automated liquid handling apparatus (e.g., a pipetting device) configured and arranged to dispense sample and reagent solutions to the surface.

Below is provided an indication of the methodology by which the optimal materials and methods useful for construction of optical test surfaces of this invention can be made. Generally, the present invention includes novel optically active test surfaces for the direct detection of an analyte. These test surfaces have an analyte-specific antibody bound to the test surface by use of an attachment layer – namely the antibody-binding proteins. Thus, the present invention provides a detection device which includes selecting an optical substrate, patterning it with antibody-binding protein, and then exposing this to the antibody for the desired analyte. The detection method involves contacting this device with a sample fluid containing the analyte of interest, and then examining the change in diffraction of transmitted or reflected light by observing whether a diffraction pattern is formed.

The present invention has a broad range of applications and may be utilized in a variety of specific binding pair assay methods. For example, the devices of this invention can be used in immunoassay methods for either

antigen or antibody detection. The devices may be adapted for use in direct, indirect, or competitive detection schemes.

In one embodiment of the present invention, the antibody-binding protein layer has the following general formula:



X is optional as a means of allowing chemisorption to a metal or metal oxide. For example, X may be asymmetrical or symmetrical disulfide (-R'SSY', -RSSY), sulfide (-R'SY', -RSY), diselenide (-R'Se-SeY'), selenide (-R'SeY', -RSeY), thiol (-SH), nitrile (-CN), isonitrile, nitro (-NO<sub>2</sub>), selenol (-SeH), trivalent phosphorous compounds, isothiocyanate, xanthate, thiocarbamate, phosphine, thioacid or dithioacid, carboxylic acids, hydroxylic acids, and hydroxamic acids.

P represents the antibody-binding proteins which may be derivatized with X. Ab represents the antibody specific to the desired analyte.

The stamp may be applied in air, or under a fluid such as water to prevent excess diffusion of the protein material. For large-scale or continuous printing processes, it is most desirable to print in air, since shorter contact times are desirable for those processes.

In one embodiment of the present invention, the pattern is formed on the metalized thermoplastic polymer with the antibody-binding protein layer. In another embodiment of the present invention, the relief of the pattern is formed with the antibody-binding protein layer. After the stamping process, the metalized areas on the plastic may optionally be passivated or blocked, for example, with a reagent such as  $\beta$ -casein. Preferably this is done prior to exposure to the antibody.

This invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and equivalents thereof, which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention.

5

## EXAMPLES

## EXAMPLE 1

10

5

15

10

20

Antibody-conjugated polystyrene particles were produced by carbodiimide coupling with ethyldimethylaminocarbodiimide (EDAC, bottle No. 3 of Polysciences kit, Catalog No. 19539). For this example, 0.125 mL of a 10% suspension of 0.5 micron diameter blue carboxylated particles (Bangs Laboratories; Fishers, Indiana; Cat #D0005070CB) were activated with an aqueous solution of the EDAC for 1-4 hours, rinsed, then exposed to 300 micrograms of a monoclonal antibody to luteinizing hormone, alpha subunit, (Fitzgerald Industries, Cat. No. 10-L10, Clone No. M94136). The particles were again rinsed, blocked with bovine serum albumin, and stored at 2.5% concentration in phosphate buffered saline.

15

25

30

35

40

45

20

25

30

35

50

A 10 mM aqueous stock solution of Sulfo-LC-SPDP (Pierce Chemical Co.; Rockford, IL) was prepared by dissolving 1.3 mg Sulfo-LC-SPDP into 2.07 mL de-ionized water. The conjugation reaction was carried out in phosphate buffered saline (PBS) containing 20 mM sodium phosphate buffer, 150 mM NaCl, 1 mM EDTA, and 0.02% sodium azide at pH 7.5. One milligram of lyophilized Protein A or Protein G was dissolved in 450 microliters PBS, and 50 microliters of Sulfo-LC-SPDP stock solution was added to the antibody solution. The mixture was allowed to react at room temperature for 60 minutes. The sample was applied to a 5-mL desalting polyacrylamide column previously equilibrated with 5 bed volumes (25 mL) of PBS. Fractions were eluted using PBS as the elution buffer, and the protein in the fractions was monitored using a COOMASSIE<sup>®</sup> Plus Protein Assay (Pierce Chemical Co.). Typically, 50  $\mu$ L of the COOMASSIE<sup>®</sup> reagent was mixed with 50  $\mu$ L of each fraction in a micro-titer plate. The COOMASSIE<sup>®</sup> reagent reacted with the protein, producing a blue color, the intensity of which was dependent upon the amount of protein present in the fraction. The fractions which produced the most intense blue color were those containing the majority of the protein eluted. These fractions were pooled together as the disulfide form of the final derivatized product. This was typically the form used for contact printing.

Optionally, the disulfide-pyridyl group present on the disulfide form of the thiolated binder can be reduced to a thiol group in a reduction reaction. Instead of desalting on a column equilibrated with PBS, the derivatized protein was desalted on a column equilibrated with an acetate buffer (100mM

55

5 sodium acetate buffer, 100 mM NaCl, pH 4.5). The acidic pH of this acetate  
buffer acts to protect any disulfide bonds present on the native protein from  
undesired reduction. In the reduction reaction, 12 mg of dithiothreitol (DTT)  
10 is dissolved in 500 mL acetate buffer and added to 1 mL of the SPDP  
5 derivatized protein. The reaction mixture was incubated for 30 minutes at  
room temperature, and desalted on a 5 mL desalting column equilibrated  
with 5 bed volumes (25 mL) of acetate buffer. The protein content of the  
15 fractions eluted was again monitored by the COOMASSIE® Protein Assay  
reagent as described above, and the fractions containing the greatest amount  
10 of protein were pooled for subsequent contact printing.

Both the disulfide and reduced forms of the thiolated binders were  
20 stored in aqueous solution at 4 °C until used for contact printing.

A gold/MYLAR® film was pre-treated (or blocked) with a 5 mg/mL  
15 beta casein solution for 10 minutes, then thoroughly rinsed and dried under  
an air stream. A PDMS stamp of 10-micron circles was coated with thiolated  
25 antibody-binding protein by placing the stamp face down in a 0.5 mg/mL  
thiolated Protein A (or Protein G) solution and soaking for 10 minutes. A  
strong air stream was used to thoroughly dry the surface of the stamp. The  
coated stamp is placed in contact with the gold/MYLAR® for 5 minutes, then  
30 removed. The resulting printed gold/MYLAR® was rinsed in distilled water,  
and dried.

The sensor was then exposed to an antibody solution (e.g., a 2 ug/mL  
35 PBS solution of monoclonal antibody to luteinizing hormone-beta, Catalog  
No. 10-L15, Clone No. M94187, Fitzgerald Industries International, Inc.;  
25 Concord, MA) for 30 minutes, followed by rinsing, and air-drying.

The sensor sample was exposed to a 2 ug/mL aqueous solution (with  
40 1% bovine serum albumin) of goat anti-mouse HRP (horse radish peroxidase  
labeled) by placing a droplet of the solution on top of the sensor surface for  
30-60 minutes at room temperature. The sample was rinsed with 0.02%  
30 Tween 20 solution, then distilled water. A subsequent exposure to a TMB  
membrane enhancer solution (e.g., a 10:1 v/v mixture of Kirkegaard and  
45 Perry Laboratories' reagents Cat No. 50-76-18 and Cat. No. 50-77-01) was  
done by placing the TMB solution on the sensor sample for 10 minutes. This  
caused the development of a blue precipitate in the circles or features, as well  
35 as a diffraction image to form upon irradiation with a point light source.

Optionally, the analyte solution (e.g., luteinizing hormone for this  
50 example) is mixed with microparticles (typically 50-70 microliters of analyte

5 solution with 10-20 microliters of 1.5-2.5% antibody-conjugated particle  
suspension), and placed on top of the sensor (typically a 1 cm square sensor  
sample is used). After 5-10 minutes, a nitrocellulose disk (5 or 8 micron pore  
10 size, Sigma No. N3771 or N4146) with a small hole punched out of the  
5 center is placed on top of the sensor. This acts to wick away excess fluid and  
unbound microparticles. At that time, a point light source is transmitted  
through the sensor sample (using the small hole in the nitrocellulose). If the  
15 analyte was present, then a diffraction image is seen on the other side of the  
light beam.

#### 10 EXAMPLE 2

20 Antibody-conjugated polystyrene particles were produced by  
carbodiimide coupling with ethyldimethylaminocarbodiimide (EDAC, bottle  
No. 3 of Polysciences kit, Catalog No. 19539). For this example, 0.125 mL  
15 of a 10% suspension of 0.5 micron diameter blue carboxylated particles  
(Bangs Laboratories; Fishers, Indiana; Cat. No. D0005070CB) were activated  
25 with an aqueous solution of the EDAC for 1-4 hours, rinsed, then exposed to  
300 micrograms of a polyclonal antibody to IgE (such as chicken anti-IgE in  
order to be unreactive to the patterned Protein A). The particles were again  
20 rinsed, blocked with bovine serum albumin, and stored at 2.5% concentration  
in phosphate buffered saline.

35 A 10 mM aqueous stock solution of Sulfo-LC-SPDP (Pierce Chemical  
Co.; Rockford, IL) was prepared by dissolving 1.3 mg Sulfo-LC-SPDP into  
2.07 mL de-ionized water. The conjugation reaction was carried out in  
25 phosphate buffered saline (PBS) containing 20 mM sodium phosphate buffer,  
150 mM NaCl, 1 mM EDTA, and 0.02% sodium azide at pH 7.5. One  
milligram of lyophilized Protein A was dissolved in 450 microliters PBS, and  
40 50 microliters of Sulfo-LC-SPDP stock solution was added to the antibody  
solution. The mixture was allowed to react at room temperature for 60  
30 minutes. The sample was applied to a 5-mL desalting polyacrylamide column  
previously equilibrated with 5 bed volumes (25 mL) of PBS. Fractions were  
45 eluted using PBS as the elution buffer, and the protein in the fractions were  
monitored using a COOMASSIE® Plus Protein Assay (Pierce Chemical Co.).  
Typically, 50 µL of the COOMASSIE® reagent was mixed with 50 µL of  
35 each fraction in a micro-titer plate. The COOMASSIE® reagent reacted with  
the protein, producing a blue color, the intensity of which was dependent  
50 upon the amount of protein present in the fraction. The fractions which

5 produced the most intense blue color were those containing the majority of  
the protein eluted. These fractions were pooled together as the disulfide form  
of the final derivatized product. This was typically the form used for contact  
10 printing.

5 Optionally, the disulfide-pyridyl group present on the disulfide form of  
the thiolated binder can be reduced to a thiol group in a reduction reaction.  
Instead of desalting on a column equilibrated with PBS, the derivatized  
15 protein was desalted on a column equilibrated with an acetate buffer (100mM  
sodium acetate buffer, 100 mM NaCl, pH 4.5). The acidic pH of this acetate  
20 buffer acts to protect any disulfide bonds present on the native protein from  
undesired reduction. In the reduction reaction, 12 mg of dithiothreitol (DTT)  
was dissolved in 500 mL acetate buffer and added to 1 mL of the SPDP  
derivatized protein. The reaction mixture was incubated for 30 minutes at  
15 room temperature, and desalted on a 5 mL desalting column equilibrated  
with 5 bed volumes (25 mL) of acetate buffer. The protein content of the  
25 fractions eluted was again monitored by the COOMASSIE® Protein Assay  
reagent as described above, and the fractions containing the greatest amount  
of protein were pooled for subsequent contact printing.

Both the disulfide and reduced forms of the thiolated binders were  
30 stored in aqueous solution at 4°C until used for contact printing.

A gold/MYLAR® film was pre-treated (or blocked) with a 5 mg/mL  
beta casein solution for 10 minutes, then thoroughly rinsed and dried under  
an air stream. A PDMS stamp of 10-micron circles was coated with thiolated  
35 antibody-binding protein by placing the stamp face down in a 0.5 mg/mL  
thiolated Protein A solution and soaking for 10 minutes. A strong air stream  
was used to thoroughly dry the surface of the stamp. The coated stamp was  
placed in contact with the gold/MYLAR® for 5 minutes, then removed. The  
40 resulting printed gold/MYLAR® was rinsed in distilled water, and dried.

The analyte solution (typically 50-70 microliters at 2 µg/mL PBS  
45 solution of IgE (Catalog No. 30-A105, Fitzgerald Industries International, Inc.;  
Concord, MA) is placed on top of the sensor (typically a 1 cm square) for 0-  
20 minutes, followed by 10-20 microliters of 1.5-2.5% antibody-conjugated  
particle suspension for an additional 5-20 minutes. A nitrocellulose disk (5 or  
35 8 micron pore size, Sigma No. N3771 or N4146) with a small hole punched  
out of the center is then placed on top of the sensor. This acts to wick away  
excess fluid and unbound microparticles. At that time, a point light source is  
50 transmitted through the sensor sample (using the small hole in the



5

nitrocellulose). If the analyte was present, then a diffraction image is seen on the other side of the light beam, as illustrated.

10

15

20

25

30

35

40

45

50

55

## Claims

5

10

15

20

25

30

35

40

45

50

55

5

We claim:

10

5

1. A biosensor comprising:  
a polymer film; and  
an antibody-binding protein layer printed in a pattern onto the polymer film wherein the antibody-binding protein layer has an antibody thereon that is specific for an analyte.

15

10

2. The biosensor of Claim 1, wherein the antibody-binding protein layer is printed in a pattern such that when the biosensor binds the analyte, the biosensor diffracts transmitted light to form a diffraction pattern.

20

15

3. The biosensor of Claim 2, wherein the diffraction pattern is visible with an unaided eye.

25

4. The biosensor of Claim 1, wherein the polymer film further comprises a metal coating.

30

20

5. The biosensor of Claim 4, wherein the metal is selected from gold, silver, chromium, nickel, platinum, aluminum, iron, copper, zirconium, or oxides thereof.

35

25

6. The biosensor of Claim 4, wherein the metal is gold.

7. The biosensor of Claim 6, wherein the gold coating is between approximately 1 nanometer and 1000 nanometers in thickness.

40

30

8. The biosensor of Claim 1, wherein the polymer film is selected from polyethylene-terephthalate, acrylonitrile-butadiene-styrene, acrylonitrile-methyl acrylate copolymer, cellophane, cellulosic polymers such as ethyl cellulose, cellulose acetate, cellulose acetate butyrate, cellulose propionate, cellulose triacetate, cellulose triacetate, polyethylene, polyethylene - vinyl acetate copolymers, ionomers (ethylene polymers) polyethylene-nylon copolymers, polypropylene, methyl pentene polymers, polyvinyl fluoride, or aromatic polysulfones.

45

35

50

55

5

9. The biosensor of Claim 8, wherein the polymer film is polyethylene-terephthalate.

10

5

10. The biosensor of Claim 1, wherein the polymer film is optically transparent.

15

11. The biosensor of Claim 1, wherein the polymer film has an optical transparency between 5% and 95%.

10

12. The biosensor of Claim 1, wherein the polymer film has an optical transparency between approximately 20% and 80%.

20

13. The biosensor of Claim 1, wherein the antibody-binding protein layer is formed from compounds with the following general formula:

15

25



wherein:

30

20

X is reactive with the metal or metal oxide on the polymer film;

P is an antibody-binding protein; and

Ab is an antibody specific to a desired analyte.

35

25

14. The biosensor of Claim 13, wherein:

X is a asymmetrical or symmetrical disulfide (-SSY', -SSY), sulfide (-SY', SY), diselenide (-Se-SeY'), selenide (-SeY', -SeY), thiol (-SH), nitrile (-CN), isonitrile, nitro (-NO<sub>2</sub>), selenol (-SeH), trivalent phosphorous compounds, isothiocyanate, xanthate, thiocarbamate, phosphine, thioacid or dithioacid, carboxylic acids, hydroxylic acids, and hydroxamic acids.

40

45

50

55

5

10

5

15

10

20

15

25

30

35

40

30

45

35

50

55

15. The biosensor of Claim 1, wherein the analyte is selected from bacteria, yeast, fungus, virus, rheumatoid factor, IgG, IgM, IgA and IgE antibodies, carcinoembryonic antigen, streptococcus Group A antigen, viral antigens, antigens associated with autoimmune disease, allergens, tumor antigens, streptococcus Group B antigen, HIV I or HIV II antigen, antibodies, viruses, antigens specific to RSV, antigen, enzyme, hormone, polysaccharide, protein, lipid, carbohydrate, drug, nucleic acid, *Neisseria meningitidis* groups A, B, C, Y and W sub 135, *Streptococcus pneumoniae*, *E. coli* K1, *Haemophilus influenza* type B, an antigen derived from microorganisms, a hapten, a drug of abuse, a therapeutic drug, an environmental agent, or antigens specific to hepatitis.

16. The biosensor of Claim 15, wherein the analyte is bacteria, yeast, fungus or virus.

17. The biosensor of Claim 16, wherein the fungus is *Candida species*.

18. The biosensor of Claim 16, wherein the bacteria is *Salmonella species*.

19. The biosensor of Claim 1, wherein the protein material is selected from Protein A, Protein G, Protein L, or a recombinant form thereof.

20. A method of making a biosensor comprising printing a pattern of antibody-binding protein layer with a subsequent layer of antibody on the polymer film.

21. The method of Claim 20, wherein the antibody-binding protein layer is printed in a pattern such that when the biosensor binds an analyte, the biosensor diffracts transmitted light to form a diffraction pattern.

22. The method of Claim 20, wherein the polymer film further comprises a metal coating.

5

23. The method of Claim 22, wherein the metal is selected from gold, silver, chromium, nickel, platinum, aluminum, iron, copper, zirconium, or oxides thereof.

10

5

24. The method of Claim 22, wherein the metal is gold.

15

25. The method of Claim 24, wherein the gold coating is between approximately 1 nanometer and 1000 nanometers in thickness.

10

20

15

25

26. The method of Claim 20, wherein the polymer film is selected from polyethylene-terephthalate, acrylonitrile-butadiene-styrene, acrylonitrile-methyl acrylate copolymer, cellophane, cellulosic polymers such as ethyl cellulose, cellulose acetate, cellulose acetate butyrate, cellulose propionate, cellulose triacetate, cellulose triacetate, polyethylene, polyethylene - vinyl acetate copolymers, ionomers (ethylene polymers) polyethylene-nylon copolymers, polypropylene, methyl pentene polymers, polyvinyl fluoride, or aromatic polysulfones.

30

20

27. The method of Claim 26, wherein the polymer film is polyethylene-terephthalate.

35

25

28. The method of Claim 20, wherein the polymer film is optically transparent.

40

30

29. The method of Claim 28, wherein the polymer film has an optical transparency between 5% and 95%.

30. The method of Claim 28, wherein the polymer film has an optical transparency between approximately 20% and 80%.

45

50

55

5  
31. The method of Claim 20, wherein the antibody-binding protein layer is formed from compounds with the following general formula:



wherein:

X is reactive with the metal or metal oxide on the polymer film;

15 P is an antibody-binding protein; and

Ab is an antibody specific to a desired analyte.

10  
32. The method of Claim 31, wherein:

20 X is a asymmetrical or symmetrical disulfide (-SSY', -SSY), sulfide (-'SY', SY), diselenide (-'Se-SeY'), selenide (-SeY', -SeY), thiol (-SH), nitrile (-CN), isonitrile, nitro (-NO<sub>2</sub>), selenol (-SeH), trivalent phosphorous compounds, isothiocyanate, xanthate, thiocarbamate, phosphine, thioacid or  
15 dithioacid, carboxylic acids, hydroxylic acids, and hydroxamic acids.

33. The method of Claim 20, wherein the analyte is selected from  
20 bacteria, yeast, fungus, virus, rheumatoid factor, IgG, IgM, IgA and IgE antibodies, carcinoembryonic antigen, streptococcus Group A antigen, viral antigens, antigens associated with autoimmune disease, allergens, tumor antigens, streptococcus Group B antigen, HIV I or HIV II antigen, antibodies, viruses, antigens specific to RSV, antigen, enzyme, hormone, polysaccharide,  
35 protein, lipid, carbohydrate, drug, nucleic acid, *Neisseria meningitidis* groups A, B, C, Y and W sub 135, *Streptococcus pneumoniae*, *E. coli* K1, *Haemophilus influenza* type B, an antigen derived from microorganisms, a hapten, a drug of abuse, a therapeutic drug, an environmental agent, or  
40 antigens specific to hepatitis.

30  
34. The method of Claim 33, wherein the analyte is bacteria, yeast, fungus or virus.

45  
35. The method of Claim 20, wherein the protein material is selected from Protein A, Protein G, Protein L, or a recombinant form thereof.  
35

5

10

15

10

20

15

25

30

35

40

30

45

35

50

55

36. A method of detecting an analyte in a medium comprising:  
contacting the medium suspected of containing the analyte with a  
biosensing device, the biosensing device comprising:

a polymer film; and  
an antibody-binding protein layer printed in a pattern onto the polymer film  
wherein the antibody-binding protein layer has a protein material thereon that  
is specific for the analyte; and

transmitting a light through the polymer film; and  
detecting presence of the analyte bound to the protein material by  
detecting a pattern form by diffraction of the transmitted light.

37. The method of Claim 36, wherein the diffraction pattern is  
visible with an unaided eye.

38. The method of Claim 36, wherein the polymer film further  
comprises a metal coating.

39. The method of Claim 38, wherein the metal is gold.

40. A biosensor comprising:  
a polymer film; and  
an antibody-binding protein layer printed in a pattern onto the polymer  
film wherein the antibody-binding protein layer is capable of acting as a  
receptor for an analyte.

41. The biosensor of Claim 40, wherein the antibody-binding protein  
layer is printed in a pattern such that when the biosensor binds the analyte,  
the biosensor diffracts transmitted light to form a diffraction pattern.

42. The biosensor of Claim 41, wherein the diffraction pattern is  
visible with an unaided eye.

43. The biosensor of Claim 40, wherein the polymer film further  
comprises a metal coating.



5

44. The biosensor of Claim 43, wherein the metal is selected from gold, silver, chromium, nickel, platinum, aluminum, iron, copper, zirconium, or oxides thereof.

10

5

45. The biosensor of Claim 43, wherein the metal is gold.

15

46. The biosensor of Claim 45, wherein the gold coating is between approximately 1 nanometer and 1000 nanometers in thickness.

10

20

15

25

47. The biosensor of Claim 40, wherein the polymer film is selected from polyethylene-terephthalate, acrylonitrile-butadiene-styrene, acrylonitrile-methyl acrylate copolymer, cellophane, cellulosic polymers such as ethyl cellulose, cellulose acetate, cellulose acetate butyrate, cellulose propionate, cellulose triacetate, cellulose triacetate, polyethylene, polyethylene - vinyl acetate copolymers, ionomers (ethylene polymers) polyethylene-nylon copolymers, polypropylene, methyl pentene polymers, polyvinyl fluoride, or aromatic polysulfones.

30

20

48. The biosensor of Claim 47, wherein the polymer film is polyethylene-terephthalate.

35

25

49. The biosensor of Claim 40, wherein the polymer film is optically transparent.

40

30

50. The biosensor of Claim 40, wherein the polymer film has an optical transparency between 5% and 95%.

51. The biosensor of Claim 40, wherein the polymer film has an optical transparency between approximately 20% and 80%.

45

50

55

5

52. The biosensor of Claim 40, wherein the antibody-binding protein layer is formed from compounds with the following general formula:

10

X-P

5

wherein:

X is reactive with the metal or metal oxide on the polymer film;

15

P is an antibody-binding protein; and

10

53. The biosensor of Claim 52, wherein:

20

X is a asymmetrical or symmetrical disulfide (-SSY', -SSY), sulfide (-SY', SY), diselenide (-Se-SeY'), selenide (-SeY', -SeY), thiol (-SH), nitrile (-CN), isonitrile, nitro (-NO<sub>2</sub>), selenol (-SeH), trivalent phosphorous compounds, isothiocyanate, xanthate, thiocarbamate, phosphine, thioacid or dithioacid, carboxylic acids, hydroxylic acids, and hydroxamic acids.

15

25

54. The biosensor of Claim 40, wherein the analyte is selected from antibodies such as IgG, IgM, IgA and IgE.

30

20

55. The biosensor of Claim 40, wherein the protein material is selected from Protein A, Protein G, Protein L, or a recombinant form thereof.

35

25


56. The biosensor of Claim 40, further comprising a diffraction enhancing element, wherein the diffraction enhancing element includes an antibody that is capable of binding to the analyte.

40


45

50

55



**Fig. 1**



**Fig. 2**

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/US 99/27727

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 G01N33/543 G01N21/47		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 G01N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 27417 A (KIMBERLY CLARK CO) 25 June 1998 (1998-06-25) page 10, line 6 -page 11, line 5 claims ---	1-51
X	WO 96 09532 A (ABBOTT LAB) 28 March 1996 (1996-03-28)  page 9, line 26-30 page 13, line 30 -page 14, line 7 page 27, line 19-27 --- -/--	1-6, 8, 13, 15, 20, 24, 26, 31-33, 36-45, 47
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claims or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "G" document member of the same patent family		
Date of the actual completion of the international search 14 March 2000		Date of mailing of the international search report 22/03/2000
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016		Authorized officer Muñoz, M

Form PCT/ISA/210 (second sheet) (July 1992)

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/US 99/27727

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BLAWAS A S ET AL: "Protein patterning" BIOMATERIALS.GB,ELSEVIER SCIENCE PUBLISHERS BV., BARKING, vol. 19, no. 7-9, 5 April 1998 (1998-04-05), pages 595-609, XP004120826 ISSN: 0142-9612 the whole document	1-51
A	WO 98 21571 A (BINDER ANDRES ;CIBA GEIGY AG (CH); EHRAT MARKUS (CH); OROSZLAN PET) 22 May 1998 (1998-05-22) claims 1,2,10-13	1-51

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter. nat. Application No

PCT/US 99/27727

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9827417 A	25-06-1998	US 5922550 A	13-07-1999
		AU 5615698 A	15-07-1998
		EP 0946865 A	06-10-1999
WO 9609532 A	28-03-1996	US 5599668 A	04-02-1997
		AU 3636295 A	09-04-1996
		CA 2197321 A	28-03-1996
		EP 0783683 A	16-07-1997
		JP 10506190 T	16-06-1998
		US 5843651 A	01-12-1998
WO 9821571 A	22-05-1998	AU 5479998 A	03-06-1998